文献速递甲状腺疾病

利妥昔单抗辅助治疗年轻Graves病患者的探索性试验

Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

CONTEXT: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD).…

要点

  • 12-20岁Graves甲亢患者接受利妥昔单抗500 mg联合12个月ATD,24个月缓解率48%。
  • 缓解率超过A'Hern设计临界值9,提示值得开展随机对照试验。
  • 28周时B淋巴细胞计数占基线百分比与缓解可能性相关。

核心结论

  • 辅助利妥昔单抗联合12个月ATD可能提高年轻Graves甲亢患者的缓解可能性。
  • 有必要在年轻Graves甲亢患者中开展辅助利妥昔单抗的随机对照试验。

研究设计与样本

  • 开放标签、多中心、单臂2期试验,纳入27例12-20岁Graves甲亢患者。
  • 采用A'Hern设计区分40%的可喜缓解率与20%的不可接受缓解率。
  • 干预为500 mg利妥昔单抗联合12个月ATD,ATD根据甲状腺功能滴定,12个月后停用,24个月评估主要结局。

主要发现

  • 27例参与者完成试验,无与治疗相关的严重副作用。
  • 12个月时21/27例每日卡比马唑剂量小于5 mg。
  • 28周时B淋巴细胞计数占基线百分比与缓解可能性相关。

关键数值与推荐

  • 24个月复发定义:促甲状腺激素抑制且游离三碘甲状腺原氨酸升高,或12-24个月间接受ATD,或接受甲状腺手术/放射性碘。
  • A'Hern设计临界值为9。
  • 可喜缓解率为40%,不可接受缓解率为20%。

临床怎么用

  • 对于12-20岁Graves甲亢患者,可考虑在12个月ATD基础上辅助利妥昔单抗以提高缓解机会。
  • 治疗期间需监测B淋巴细胞计数,28周时占基线百分比可能提示缓解可能性。

局限性

  • 单臂设计,无对照组,无法确定利妥昔单抗的相对疗效。
  • 样本量小(27例),结果需随机对照试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Remission rates in young people with Graves hyperthyroidism are less than 25% after 2 years of thionamide antithyroid drug (ATD). OBJECTIVE: We explored whether rituximab (RTX), a B-lymphocyte-depleting agent, would increase remission rates when administered with a short course of ATD. METHODS: This was an open-label, multicenter, single-arm, phase 2 trial in young people (ages, 12-20 years) with Graves hyperthyroidism. An A'Hern design was used to distinguish an encouraging remission rate (40%) from an unacceptable rate (20%). Participants presenting with Graves hyperthyroidism received 500 mg RTX and 12 months of ATD titrated according to thyroid function. ATDs were stopped after 12 months and primary outcome assessed at 24 months. Participants had relapsed at 24 months if thyrotropin was suppressed and free 3,5,3'-triiodothyronine was raised; they had received ATD between months 12 and 24; or they had thyroid surgery/radioiodine. RESULTS: A total of 27 participants were recruited and completed the trial with no serious side effects linked to treatment. Daily carbimazole dose at 12 months was less than 5 mg in 21 of 27 participants. Thirteen of 27 participants were in remission at 24 months (48%, 90% one-sided CI, 35%-100%); this exceeded the critical value (9) for the A'Hern design and provided evidence of a promising remission rate. B-lymphocyte count at 28 weeks, expressed as a percentage of baseline, was related to likelihood of remission. CONCLUSION: Adjuvant RTX, administered with a 12-month course of ATD, may increase the likelihood of remission in young people with Graves hyperthyroidism. A randomized trial of adjuvant RTX in young people with Graves hyperthyroidism is warranted.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Cheetham TD, Cole M, Abinun M, et al. Adjuvant Rituximab-Exploratory Trial in Young People With Graves Disease. J Clin Endocrinol Metab. 2022. PMID: 34687316. doi:10.1210/clinem/dgab763

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。